BPG is committed to discovery and dissemination of knowledge
Featured Articles
1/27/2019 7:09:08 AM | Browse: 122 | Download: 47
Publication Name World Journal of Hepatology
Manuscript ID 42543
Country of Manuscript Source United States
Received
2018-09-27 03:36
Peer-Review Started
2018-09-27 04:25
To Make the First Decision
2018-10-17 01:28
Return for Revision
2018-10-19 04:32
Revised
2018-11-14 01:09
Second Decision
2018-12-29 02:13
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2019-01-01 05:56
Articles in Press
2019-01-01 05:56
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2019-01-24 09:03
Publish the Manuscript Online
2019-01-27 07:04
ISSN 1948-5182 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Specialty Gastroenterology and Hepatology
Manuscript type Minireviews
Article Title Persistent risk for new, subsequent new and recurrent hepatocellular carcinoma despite successful anti-hepatitis B virus therapy and tumor ablation: The need for hepatitis B virus cure
Manuscript Source Unsolicited Manuscript
All Author List Brianna J Shinn, Aaron Martin, Robert M Coben, Mitchell I Conn, Jorge Prieto, Howard Kroop, Anthony J DiMarino and Hie-Won Hann
Funding Agency and Grant Number
Correspondence To Hie-Won Hann, MD, FAASLD, Professor, Liver Disease Prevention Center, Division of Gastroenterology and Hepatology, Thomas Jefferson University Hospital, 1025 Walnut Street, Philadelphia, PA19107, United States. hie-won.hann@jefferson.edu
Keywords Hepatitis B; Hepatocellular carcinoma; Antiviral therapy; Persistent Risk for hepatocellular carcinoma; Tumor ablation
Core Tip Despite the advances in the management of hepatitis B virus (HBV) infection and HBV-associated hepatocellular carcinoma (HCC), the risk for new, subsequent new and recurrent HCC persists even after over a decade of antiviral therapy and initial tumor ablation. This is due to the inability of the current antiviral therapy to eliminate the cccDNA from the hepatocyte nucleus. There is a great need for an HBV cure drug.
Publish Date 2019-01-27 07:04
Citation Shinn BJ, Martin A, Coben RM, Conn MI, Prieto J, Kroop H, DiMarino AJ, Hann HW. Persistent risk for new, subsequent new and recurrent hepatocellular carcinoma despite successful anti-hepatitis B virus therapy and tumor ablation: The need for hepatitis B virus cure. World J Hepatol 2019; 11(1): 65-73
Url https://www.wjgnet.com/1948-5182/full/v11/i1/65.htm
DOI https://dx.doi.org/10.4254/wjh.v11.i1.65
Full Article (PDF) WJH-11-65.pdf
Full Article (Word) WJH-11-65.docx
Manuscript File 42543-Review.docx
Answering Reviewers 42543-Answering reviewers.pdf
Audio Core Tip 42543-Audio core tip.mp3
Conflict-of-Interest Disclosure Form 42543-Conflict-of-interest statement.pdf
Copyright License Agreement 42543-Copyright license agreement.pdf
Peer-review Report 42543-Peer-review(s).pdf
Scientific Misconduct Check 42543-Scientific misconduct check.pdf
Scientific Editor Work List 42543-Scientific editor work list.pdf